AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s new liver function trial could shape future dosing rules for two pipeline drugs, AZD9550 and AZD6234. The Phase I study, titled “A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234,” tests how liver problems change drug handling and side effects.
The drugs, AZD6234 and AZD9550, are given as single shots under the skin. They are being checked to see how safe they are and how the body absorbs them in people with different levels of liver function.
The trial is interventional and non-randomised, so patients are placed into groups based on liver status rather than by chance. It is open-label, meaning doctors and patients know which drug is used, and the main goal is to understand drug behaviour and safety, not direct treatment benefit.
There are three parallel groups. One has severe liver damage, one has moderate damage, and one has normal liver function matched by age, sex, and body size, which helps investors understand how broad any future label might be.
The study was first submitted on 2026-03-11, showing it is a fresh early-stage effort in AstraZeneca’s pipeline. The most recent update on 2026-05-04 confirms active set-up and recruitment work, with primary and final completion still ahead and no posted results yet.
For investors in AZN, this update is a small but useful signal of ongoing R&D in complex patients, which can support pricing power if these assets advance. Success could improve confidence in AstraZeneca’s late-decade portfolio, while setbacks may be viewed as routine Phase I risk, especially as peers also race to tailor dosing for patients with liver issues.
The study remains underway and updated, with more details available on the ClinicalTrials portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.